There are 2789 resources available
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1145P - Reliable detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue: A new diagnostic benchmark for somatic BRCA testing
Presenter: Nadejda Valtcheva
Session: ePoster Display
1146P - Closing the target gap: A computational approach to optimizing therapeutic selection for cancer patients
Presenter: Mikhail Grushko
Session: ePoster Display
1147P - AI-based detection of molecular biomarkers directly from H&E scanned slide
Presenter: Nir Peled
Session: ePoster Display
1148P - Identification and validation of RET fusions in lung adenocarcinoma through DNA and RNA sequencing
Presenter: Yuchen Han
Session: ePoster Display
1149P - An automated platform for rapid drug screening in patient-derived micro-organospheres
Presenter: Zhaohui Wang
Session: ePoster Display
1150TiP - A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Presenter: Kim Margolin
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1086P - IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Presenter: BIN LIAN
Session: ePoster Display
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display